Trial Profile
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of SM04690 Injected in the Target Knee Joint of Moderately to Severely Symptomatic Osteoarthritis Subjects
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 11 Jul 2023
Price :
$35
*
At a glance
- Drugs Lorecivivint (Primary)
- Indications Osteoarthritis
- Focus Proof of concept; Therapeutic Use
- Sponsors Biosplice Therapeutics; Samumed
- 03 Jun 2023 Pooled analysis of two phase 2 trails (NCT02536833, NCT03122860) and two Phase 3 trials (NCT04385303, NCT03928184) presented at the 24th Annual Congress of the European League Against Rheumatism.
- 14 Nov 2022 Post hoc pooled results presented at the ACR Convergence 2022.
- 05 Jun 2021 Results of post-hoc efficacy analysis from three clinical studies: NCT02951026, NCT02536833 and NCT03122860 presented at the 22nd Annual Congress of the European League Against Rheumatism